Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
THLD's Cash to Debt is ranked higher than
96% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. THLD: No Debt )
THLD' s 10-Year Cash to Debt Range
Min: 17.14   Max: No Debt
Current: No Debt

Equity to Asset -0.27
THLD's Equity to Asset is ranked higher than
51% of the 937 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. THLD: -0.27 )
THLD' s 10-Year Equity to Asset Range
Min: -0.86   Max: 0.88
Current: -0.27

-0.86
0.88
Interest Coverage No Debt
THLD's Interest Coverage is ranked higher than
93% of the 582 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. THLD: No Debt )
THLD' s 10-Year Interest Coverage Range
Min: 725.64   Max: 9999.99
Current: No Debt

725.64
9999.99
F-Score: 3
Z-Score: -5.57
M-Score: -2.35
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -220.82
THLD's Operating margin (%) is ranked higher than
65% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: -75.73 vs. THLD: -220.82 )
THLD' s 10-Year Operating margin (%) Range
Min: -48445.16   Max: -208.28
Current: -220.82

-48445.16
-208.28
Net-margin (%) -162.84
THLD's Net-margin (%) is ranked higher than
68% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: -78.15 vs. THLD: -162.84 )
THLD' s 10-Year Net-margin (%) Range
Min: -41375.81   Max: -227.41
Current: -162.84

-41375.81
-227.41
ROA (%) -25.19
THLD's ROA (%) is ranked higher than
75% of the 1253 Companies
in the Global Biotechnology industry.

( Industry Median: -27.49 vs. THLD: -25.19 )
THLD' s 10-Year ROA (%) Range
Min: -132.78   Max: -29.35
Current: -25.19

-132.78
-29.35
ROC (Joel Greenblatt) (%) -4693.41
THLD's ROC (Joel Greenblatt) (%) is ranked higher than
58% of the 1227 Companies
in the Global Biotechnology industry.

( Industry Median: -437.61 vs. THLD: -4693.41 )
THLD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -8350.75   Max: 2566.56
Current: -4693.41

-8350.75
2566.56
EBITDA Growth (3Y)(%) -15.70
THLD's EBITDA Growth (3Y)(%) is ranked higher than
69% of the 714 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. THLD: -15.70 )
THLD' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -73.4   Max: -15.7
Current: -15.7

-73.4
-15.7
EPS Growth (3Y)(%) -4.40
THLD's EPS Growth (3Y)(%) is ranked higher than
78% of the 729 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. THLD: -4.40 )
THLD' s 10-Year EPS Growth (3Y)(%) Range
Min: -85.5   Max: 2.7
Current: -4.4

-85.5
2.7
» THLD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

THLD Guru Trades in Q4 2013

Steven Cohen 17,841 sh (+75.65%)
Jean-Marie Eveillard 200,000 sh (unchged)
Jim Simons 61,064 sh (-77.37%)
» More
Q1 2014

THLD Guru Trades in Q1 2014

Jean-Marie Eveillard 700,000 sh (+250%)
Jim Simons 191,264 sh (+213.22%)
Steven Cohen 14,289 sh (-19.91%)
» More
Q2 2014

THLD Guru Trades in Q2 2014

Jim Simons 402,886 sh (+110.64%)
Jean-Marie Eveillard 800,000 sh (+14.29%)
» More
Q3 2014

THLD Guru Trades in Q3 2014

Jean-Marie Eveillard 1,091,700 sh (+36.46%)
Jim Simons 40,700 sh (-89.9%)
» More
» Details

Insider Trades

Latest Guru Trades with THLD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2014-09-30 Add 36.46%$3.75 - $5.03 $ 3.07-27%1091700
Jean-Marie Eveillard 2014-03-31 Add 250%0.01%$4.34 - $5.72 $ 3.07-38%700000
Jean-Marie Eveillard 2012-12-31 New Buy$3.98 - $6.55 $ 3.07-34%200000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 13.40
THLD's P/S is ranked higher than
79% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 28.14 vs. THLD: 13.40 )
THLD' s 10-Year P/S Range
Min: 1.77   Max: 1242
Current: 13.4

1.77
1242
EV-to-EBIT -3.97
THLD's EV-to-EBIT is ranked higher than
70% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. THLD: -3.97 )
THLD' s 10-Year EV-to-EBIT Range
Min: -22.4   Max: 39.3
Current: -3.97

-22.4
39.3
Current Ratio 2.97
THLD's Current Ratio is ranked higher than
65% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. THLD: 2.97 )
THLD' s 10-Year Current Ratio Range
Min: 1.48   Max: 13.48
Current: 2.97

1.48
13.48
Quick Ratio 2.97
THLD's Quick Ratio is ranked higher than
67% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. THLD: 2.97 )
THLD' s 10-Year Quick Ratio Range
Min: 1.48   Max: 13.48
Current: 2.97

1.48
13.48

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.29
THLD's Price/Median PS Value is ranked higher than
97% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. THLD: 0.29 )
THLD' s 10-Year Price/Median PS Value Range
Min: 0.07   Max: 25.36
Current: 0.29

0.07
25.36
Earnings Yield (Greenblatt) -25.20
THLD's Earnings Yield (Greenblatt) is ranked higher than
56% of the 1221 Companies
in the Global Biotechnology industry.

( Industry Median: -6.20 vs. THLD: -25.20 )
THLD' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.5   Max: 14657.5
Current: -25.2

2.5
14657.5

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:NZW1.Germany,
Threshold Pharmaceuticals, Inc. is a Delaware corporation incorporated on October 17, 2001. It's a biotechnology company focused on the discovery and development of drugs targeting the microenvironment of solid tumors as novel treatments for patients living with cancer. The microenvironment of these tissues is characterized by hypoxia or lack of oxygen. Its hypoxia activated prodrug ("HAP") product candidates, including TH-302, are designed to specifically target the hypoxic microenvironment of tumors by selective activation of the prodrug to release a potent cytotoxin. Its focus is on product candidates for the treatment of patients with cancer. Its clinical development efforts are currently engaged in TH-302, for which it entered a license and co-development agreement with Merck KGaA for development and commercialization. TH-302 is a novel drug candidate that is activated under severe hypoxic conditions and was designed to specifically target the severe hypoxic regions that are believed to be present in all solid tumors and hematologic malignancies. The production of TH-302 employs small molecule organic chemistry procedures that are standard for the pharmaceutical industry. It currently relies on contract manufacturers for the manufacture of active pharmaceutical ingredient ("API"), and final drug product of TH-302. Under its license and co-development agreement with Merck KGaA, the Company is dependent on Merck for clinical and commercial supply of TH-302, except for clinical trials for United States approval of TH-302 for soft tissue sarcoma and for any other clinical trials for which it is responsible. For these latter cases, it can obtain clinical supply directly from existing or new suppliers. It currently uses contract manufacturers to manufacture TH-302 API and TH-302 drug product. The commercial sale for pancreatic cancer, TH-302 would compete with Gemzar, marketed by Eli Lilly and Company; Tarceva, marketed by Genentech and Astellas Oncology; Abraxane marketed by Celgene; and FOLFIRINOX. The manufacturing and marketing of its potential products and its ongoing research and development activities are subject to extensive regulation by the FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries.
» More Articles for THLD

Headlines

Articles On GuruFocus.com
Encouraging Initial Data From Ongoing Phase 1/2 Trial of TH-302 Plus Bortezomib (Velcade(R)) Plus De Dec 06 2014 
Threshold Pharmaceuticals Announces Presentations and Webcasts at Upcoming Investor Meetings in Dece Nov 25 2014 
Threshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevaciz Nov 17 2014 
Threshold Pharmaceuticals Receives FDA Fast Track Designation for TH-302 for the Treatment of Previo Nov 11 2014 
Threshold Pharmaceuticals Announces Presentation and Webcast at the Stifel 2014 Healthcare Conferenc Nov 10 2014 
Threshold Pharmaceuticals Announces New Phase 1/2 Data on TH-302 in Multiple Myeloma to Be Presented Nov 06 2014 
Threshold Pharmaceuticals Announces New Phase 1/2 Data on TH-302 in Glioblastoma to be Presented at Nov 03 2014 
Threshold Pharmaceuticals' Partner Merck KGaA, Darmstadt, Germany, Completes Target Enrollment in th Nov 03 2014 
Threshold Pharmaceuticals Inc. (THLD) CEO Harold E Selick buys 47,619 Shares Mar 15 2011 
Threshold Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 04 2010 

More From Other Websites
Encouraging Initial Data From Ongoing Phase 1/2 Trial of TH-302 Plus Bortezomib (Velcade(R)) Plus... Dec 06 2014
Encouraging Initial Data From Ongoing Phase 1/2 Trial of TH-302 Plus Bortezomib (Velcade(R)) Plus... Dec 06 2014
Threshold Pharmaceuticals Announces Presentations and Webcasts at Upcoming Investor Meetings in... Nov 25 2014
Threshold Pharmaceuticals Announces Presentations and Webcasts at Upcoming Investor Meetings in... Nov 25 2014
THLD: Threshold’s Provides an Update on its Phase I/II Trial using TH-302 in Glioblastoma Nov 17 2014
Threshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus... Nov 17 2014
Threshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus... Nov 17 2014
THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Other Events Nov 12 2014
THRESHOLD PHARMACEUTICALS INC Financials Nov 11 2014
Threshold Pharmaceuticals Receives FDA Fast Track Designation for TH-302 for the Treatment of... Nov 11 2014
Threshold Pharmaceuticals Receives FDA Fast Track Designation for TH-302 for the Treatment of... Nov 11 2014
Threshold Pharmaceuticals Announces Presentation and Webcast at the Stifel 2014 Healthcare... Nov 10 2014
Threshold Pharmaceuticals Announces Presentation and Webcast at the Stifel 2014 Healthcare... Nov 10 2014
Threshold Pharmaceuticals Announces New Phase 1/2 Data on TH-302 in Multiple Myeloma to Be Presented... Nov 06 2014
Threshold Pharmaceuticals Announces New Phase 1/2 Data on TH-302 in Multiple Myeloma to Be Presented... Nov 06 2014
Threshold: A Biopharmaceutical Company focused on Hypoxia-targeted Cancer Therapy Nov 06 2014
10-Q for Threshold Pharmaceuticals, Inc. Nov 05 2014
Threshold Pharmaceuticals Announces New Phase 1/2 Data on TH-302 in Glioblastoma to be Presented at... Nov 03 2014
Threshold Pharmaceuticals' Partner Merck KGaA, Darmstadt, Germany, Completes Target Enrollment in... Nov 03 2014
THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 03 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK